BACKGROUND: Non-infectious uveitis (NIU) leads to severe visual impairment, potentially impacting on health-related quality of life (QoL). OBJECTIVES: To investigate the impact of NIU on QoL. METHODS: Eighty NIU patients and 23 healthy controls completed the 36-item Short-Form Health Survey (SF)-36. The SF-36 values were statistically analyzed to evaluate differences between patients and healthy controls and to identify correlations between SF-36 subscores and clinical/demographic data. RESULTS: NIU patients showed a decrease in the physical component summary score (P < 0.0001) compared to healthy controls, while no difference was highlighted in the mental component summary score (P = 0.97). NIU patients showed a decrease in physical functioning (P = 0.008), role-physical (P = 0.003), bodily pain (P = 0.0001), general health (P < 0.0001), and social functioning (P = 0.01). Physical functioning was lower in patients with acute anterior uveitis (AAU) than in those with panuveitis (P = 0.003). No differences were found between patients with bilateral or unilateral NIU, isolated NIU, or NIU associated with systemic diseases and with or without ocular activity. No correlations were identified between best-corrected visual acuity and SF-36 subscores. Physical functioning (P = 0.02), bodily pain (P = 0.004), and social functioning (P = 0.02) were reduced in males versus females. CONCLUSIONS: QoL is impaired in individuals with NIU, particularly in the physical domains, general health, and social functioning. AAU affects physical functioning more than panuveitis. NIU seems to affect per se QoL disregarding inflammatory activity, visual impairment, and presence of associated systemic diseases.
BACKGROUND:Non-infectious uveitis (NIU) leads to severe visual impairment, potentially impacting on health-related quality of life (QoL). OBJECTIVES: To investigate the impact of NIU on QoL. METHODS: Eighty NIU patients and 23 healthy controls completed the 36-item Short-Form Health Survey (SF)-36. The SF-36 values were statistically analyzed to evaluate differences between patients and healthy controls and to identify correlations between SF-36 subscores and clinical/demographic data. RESULTS: NIU patients showed a decrease in the physical component summary score (P < 0.0001) compared to healthy controls, while no difference was highlighted in the mental component summary score (P = 0.97). NIU patients showed a decrease in physical functioning (P = 0.008), role-physical (P = 0.003), bodily pain (P = 0.0001), general health (P < 0.0001), and social functioning (P = 0.01). Physical functioning was lower in patients with acute anterior uveitis (AAU) than in those with panuveitis (P = 0.003). No differences were found between patients with bilateral or unilateral NIU, isolated NIU, or NIU associated with systemic diseases and with or without ocular activity. No correlations were identified between best-corrected visual acuity and SF-36 subscores. Physical functioning (P = 0.02), bodily pain (P = 0.004), and social functioning (P = 0.02) were reduced in males versus females. CONCLUSIONS: QoL is impaired in individuals with NIU, particularly in the physical domains, general health, and social functioning. AAU affects physical functioning more than panuveitis. NIU seems to affect per se QoL disregarding inflammatory activity, visual impairment, and presence of associated systemic diseases.
Authors: Claudia Fabiani; Antonio Vitale; Donato Rigante; Giacomo Emmi; Giuseppe Lopalco; Jurgen Sota; Lorenzo Vannozzi; Gerardo di Scala; Silvana Guerriero; Ida Orlando; Rossella Franceschini; Marco Capozzoli; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Luca Cantarini Journal: Clin Rheumatol Date: 2018-04-18 Impact factor: 2.980
Authors: Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Alice Bitossi; Giuseppe Lopalco; Jurgen Sota; Silvana Guerriero; Ida Orlando; Marco Capozzoli; Fiorella Fusco; Francesco Rana; Florenzo Iannone; Bruno Frediani; Mauro Galeazzi; Lorenzo Vannozzi; Gian Marco Tosi; Luca Cantarini Journal: Clin Rheumatol Date: 2018-04-03 Impact factor: 2.980
Authors: Xurxo García-Otero; Victoria Díaz-Tomé; Rubén Varela-Fernández; Manuel Martín-Pastor; Miguel González-Barcia; José Blanco-Méndez; Cristina Mondelo-García; Maria A Bermudez; Francisco Gonzalez; Pablo Aguiar; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar Journal: Pharmaceutics Date: 2021-01-23 Impact factor: 6.321
Authors: Luca Cantarini; Claudia Fabiani; Francesca Della Casa; Antonio Vitale; Silvana Guerriero; Jurgen Sota; Rolando Cimaz; Gaafar Ragab; Piero Ruscitti; Rosa Maria R Pereira; Francesca Minoia; Emanuela Del Giudice; Giacomo Emmi; Claudia Lomater; Sara Monti; Claudia Canofari; Carla Gaggiano; Giovanni Alessio; Elisabetta Miserocchi; Alessandro Conforti; Marilia A Dagostin; Chiara Mapelli; Maria Pia Paroli; Veronica Parretti; Valeria Albano; Rosa Favale; Luca Marelli; Mohamed Tharwat Hegazy; Paola Cipriani; Isabele P B Antonelli; Valeria Caggiano; Emma Aragona; Ahmed Hatem Laymouna; Gian Marco Tosi; Maria Tarsia; Marco Cattalini; Francesco La Torre; Giuseppe Lopalco; Ewa Więsik-Szewczyk; Micol Frassi; Stefano Gentileschi; Heitor F Giordano; Bruno Frediani; Samuel K Shinjo; Donato Rigante; Petros P Sfikakis; Alberto Balistreri; Mohamed A Hussein; Rana Hussein Amin Journal: Ophthalmol Ther Date: 2022-01-31